THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [NLEM-09] ID: TIP-MED-000495

Artesunate + Sulfadoxine-Pyrimethamine (AS+SP Kit) IP

Active Ingredient / Scientific Identity: Artesunate + Sulfadoxine-Pyrimethamine • Class: National Antimalarial ACT Combi-Blister

⚖️ Compare Profile
Generic / Entity NameArtesunate + Sulfadoxine-Pyrimethamine (AS+SP Kit) IP ([NLEM-09])
Verified Indian Brands / RefFalcigo-SP (Zydus), Larinate-SP (Ipca)
Pharmacological ClassNational Antimalarial ACT Combi-Blister
Available Dosage FormsCombi-pack Tablets: Artesunate 50/100/200 mg + SP (500 mg + 25 mg)
Regulatory ClassificationSchedule H (Prescription Only — Drugs Rules, 1945)
Key Warning & Review DateVerify individual constituent ceilings and renal/hepatic dose adjustments when prescribing fixed-dose combinations.
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H (Prescription Only — Drugs Rules, 1945)✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Artesunate + Sulfadoxine-Pyrimethamine (AS+SP Kit) IP (TIP-MED-000495, Reference Code [NLEM-09]) is classified under Antimalarials (NVBDCP) as a National Antimalarial ACT Combi-Blister. Within the Indian regulatory and compendial framework, it is governed under Schedule H (Prescription Only — Drugs Rules, 1945).

Verified Indian Market Examples / Compendial Status:
Falcigo-SP (Zydus), Larinate-SP (Ipca)
Verified Indian Market Examples: Falcigo-SP (Zydus), Larinate-SP (Ipca) — Combi-pack Tablets: Artesunate 50/100/200 mg + SP (500 mg + 25 mg)
Dosage Forms & Available Strengths:
Combi-pack Tablets: Artesunate 50/100/200 mg + SP (500 mg + 25 mg)
Routes: Oral / Parenteral / Inhalational per formulation

3. Mechanism of Action & Pharmacodynamics

Complementary dual/multi-mechanism formulation (National Antimalarial ACT Combi-Blister) providing synergistic therapeutic action.

4. Therapeutic Indications & Evidence-Supported Uses

  • Approved clinical management within Antimalarials (NVBDCP) per NLEM 2022 / IP 2022 and national treatment guidelines.

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Educational Summary: Administer approved fixed-dose strength (Combi-pack Tablets: Artesunate 50/100/200 mg + SP (500 mg + 25 mg)) according to indication, organ function, and individualised titration.

Administration & Meal Timing: Administer as directed on the approved prescription label.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Component active ingredients follow their established absorption, distribution, hepatic metabolism, and renal elimination profiles.
Metabolism & Biotransformation:
Hepatic CYP450 / Phase II conjugation depending on constituent active ingredients.
Elimination & Renal Adjustment:
Avoid or adjust fixed-dose combination if eGFR/CrCl falls below threshold for any constituent.
Hepatic Impairment Considerations:
Use with caution or avoid in moderate-to-severe hepatic impairment.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Hypersensitivity to any constituent active ingredient or excipient; severe organ impairment contraindicated for individual components.

Key Clinical Precautions: Verify individual constituent ceilings and renal/hepatic dose adjustments when prescribing fixed-dose combinations.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Component-related gastrointestinal, metabolic, or hemodynamic effects; refer to constituent monographs.
Serious / Dose-Limiting Adverse Effects:
  • Severe hypersensitivity, organ toxicity, or electrolyte/metabolic derangement.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Check drug-drug interactions for all constituent active ingredients.

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical efficacy, blood pressure/glycaemic/microbiological markers, and baseline organ function.

Pharmacist Patient Counselling Points:

  • Explain dosing schedule, adherence, food timing, and warning signs for each active component.

Storage, Stability & Dispensing Safeguards: Store below 30°C protected from moisture and light. Verify exact strength ratio before dispensing.

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • National List of Essential Medicines (NLEM 2022) • CDSCO Approved FDC List

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.